Alpha-fetoprotein (AFP) producing gastric cancer (AFP ± GC) is very malignant and highly metastatic compared with common gastric cancer. However, the causal relationship between AFP production and the high malignancy of AFP-GC is unclear. We investigated AFP gene regulation in AFP-GC by an active transcription factor, HNF1 (hapatocyte nuclear factor 1) and a repressive transcription factor, ATBF1 (AT motif binding factor 1). RNase protection assays revealed that the production of AFP in gastric cancer cells did not directly associate with HNF1 expression. An inverse relation between the expressions of ATBF1 and AFP was clearly observed in gastric cancer cells. CAT assays showed the direct inhibition of AFP gene expression by ATBF1. Methylation analysis of the AFP promoter region in gastric cancer cells suggested that methylation itself could not explain the silencing of the AFP gene. Immunohistochemistry of resected clinical samples revealed that AFP producing cells lacked ATBF1 immunoreactivity. Our data suggests that the absence of ATBF1 is responsible for AFP gene expression in gastric cancer, and the absence of ATBF1 is a distinct characteristic of AFP-GC and might be important for its highly malignant nature. Oncogene (2001) 20, 869 ± 873.
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Keywords: AFP (Alpha-fetoprotein); AFP-GC (AFP producing gastric cancer); ATBF1 (AT motif binding factor 1); HNF1 (hepatocyte nuclear factor 1) Alpha-fetoprotein (AFP) is not usually present in normal adult organs, but is found in some fetal organs, proliferating hepatocytes, and some adult cancer cells such as hepatocellular carcinoma cells, yolk sac tumor cells, and gastric cancer cells (Gitlin et al., 1972; Tyner et al., 1990) . AFP is detected most frequently in hepatocellular carcinoma (more than 70% of them), less frequently in gastric cancer, and in some cases of pancreatic cancers and biliary tract tumors (McIntire et al., 1975) . Since Bourreille et al. (1970) reported the ®rst case of AFP producing gastric cancer (AFP ± GC) in 1970, many cases of advanced and early stages of AFP ± GC have been reported. AFP ± GC is reported to be one to six percent of all gastric cancers. Most cases were characterized by a high incidence of metastases to the liver and lymph nodes and lymphatic and venous invasions (Chang et al., 1992) . The 5-year survival rate of AFP ± GC patients is 8%, whereas it is 60% overall for gastric cancer patients (Chang et al., 1990) . Since there is no conclusive explanation of the role of AFP in malignancy, it is essential to elucidate the mechanism of regulation of AFP gene expression and to de®ne the nature of AFP ± GC.
AT motif binding factor 1 (ATBF1) is a transcription factor which binds to an AT rich region in the AFP regulatory element and down regulates AFP gene expression in human hepatic cells. The repressive activity of ATBF1 is thought to be due to its binding competitively with hepatocyte nuclear factor 1 (HNF1) to the AT rich region (Miura et al., 1995; Yasuda et al., 1994) . HNF1 is a strong activator of the trascription of various liver-speci®c genes in addition to the AFP gene in hepatocytes (Cereghini, 1996) . ATBF1 is the only negative regulatory factor known to be involved in AFP expression (Chen et al., 1997) .
RNase protection assays showed that two of eight gastric cancer cell lines, GCIY and ISt-1, expressed AFP mRNA, while the other six cell lines (KATO-III, HGC-27, MKN74, MKN28, MKN45 and NUGC-4) did not ( Figure 1a ). AFP production and secretion into culture media were con®rmed with an enzyme immunoassay for human AFP (data not shown). In order to characterize the AFPs produced by AFP-GC cell lines (GCIY and ISt-1), we investigated their lectinreactive pro®les since AFPs from cancers other than hepatoma exhibit lower lectin anity than AFP from hepatoma (Taketa et al., 1990) . The lectin anities of fractions (L3) from GCIY (8.3%) and ISt-1 (29.3%) were lower than that from Hep G2 (88.1%). These results indicate that the AFP produced by AFP ± GC cells is distinct from the AFP produced by the hepatoma cells. Unexpectedly, HNF1, which is the strong activator of AFP transcription in hepatoma (Cereghini, 1996) , was expressed at dierent levels in most of the cell lines, regardless of whether or not they expressed AFP mRNA ( Figure 1b ). These things indicated that AFP gene expression in gastric cancer cells is not regulated mainly by HNF1. Therefore, we analysed ATBF1, which is the only known repressor of the AFP gene. An RNase protection assay for ATBF1 mRNA, using the MD14 probe which can distinguish the ATBF1-A and -B isoforms (Figure 1d ), demonstrated that all of the non-AFP-producing gastric cancer cell lines expressed detectable levels of both ATBF1-A and -B transcripts (Figure 1c) . In all cases, the levels of ATBF1-A transcripts were 5 ± 20-fold higher than those of the ATBF1-B transcripts. In contrast, two AFP-GC cell lines, GCIY and ISt-1, expressed only trace amounts of both ATBF1-A and -B transcripts that were barely detectable even after a long exposure (Figure 1c) . In order to investigate the molecular mechanism for the absence of ATBF1 expression in AFP-GC cells (GCIY and ISt-1), we analysed the genome structure of the ATBF1-A 9.0 kb promoter region. Southern blots using a 5.6 kb probe for the ATBF1-A promoter disclosed that there was neither a deletion mutation nor a translocation in AFP-GC cells (data not shown). These results suggest that the absence of ATBF1 expression in AFP-GC cells was due to strong repression at the transcriptional level.
To examine whether ATBF1-A, a major transcript in gastric cancer cells, down-regulates AFP promoter (Hassan et al., 1998) , AFP-GC cells, were obtained from RIKEN Cell Bank. ISt-1 (Terashima et al., 1991) , another AFP-GC cells, were kindly provided by Dr Terashima. The other six gastric cancer cell lines (KATO-III, NUGC-4, MKN28, MKN45, MKN74, HGC27) that were established from gastric carcinomas (Sekiguchi et al., 1978; Koyama et al., 1990; Motoyama et al., 1986; Fujiwara et al., 1993; Matsukawa et al., 1993) (Miura et al., 1995) . MD 14 RNA probe can distinguish ATBF1-A and ATBF1-B which are generated by alternative promoter usage combined with alternative splicing activity, we performed co-transfection experiments. An ATBF1-A expression vector was transfected into GCIY and ISt-1 cells, which express an extremely low levels of ATBF1, together with the reporter plasmid, pAF5. 1-CAT, which contains the CAT gene linked to a 5.1 -kb AFP 5'-¯anking sequence (Nakata et al., 1992) . ATBF1-A eciently repressed the CAT activity (AFP promoter activity) to 44.9+3.1% in GCIY and 85.1+7.5% in ISt-1 cells (Figure 2) . These results support the notions that the abundance of ATBF1-A in AFP-negative gastric cancer cells represses AFP production and that the trace amount of ATBF1 in AFP-GC cells induces AFP production.
Another possibile mechanism for the lack of AFP gene expression in AFP-negative gastric cancer cells is DNA methylation, since the expression of a gene is down-regulated by DNA hypermethylation in its promoter region. In the case of hepatocytes, DNA hypermethylation of the AFP promoter region was detected in AFP-negative hepatocellular carcinoma (Peng et al., 1993) . We analysed the methylation state of the AFP promoter region in gastric cancer cells by MspI and HpaII digestion. Southern blot analysis revealed that there was no methylation in the AFP promoter regions of all the gastric cancer cell lines except NUGC-4 (Figure 3) . These results suggest that the repression of AFP promoter activity in gastric (Gorman et al., 1982) of transiently transfected GCIY and ISt-1 with ATBF1-A expression vector. Reporter plasmid, pAF5. 1-CAT, was described previously (Nakata et al., 1992) . Eector plasmid, pcMATBF1, was constructed by inserting the full length ATBF1-A cDNA in pcDNAI (Invitrogen). pcDNAI as a control plasmid. Cells were transfected with plasmids by the lipofection method using TransFast TM (Promega). pCH110 b-galactosidase expression plasmid (2.6 mg) (Pharmacia Biotech Inc.) was cotransfected to monitor transfection eciency. Part of the lysate was used for measuring b-galactosidase activity to normalize CAT activity. CAT activity was quanti®ed by measuring the radioactivity of acetylated and nonacetylated chloramphenicol on chromatograms. The experiment was performed three times. Error bars, SD; 3-Ac, 3-acetyl chloramphenicol; 1-Ac, 1-acetyl chloramphenicol; Cm, chloramphenicol cancer cells depends partially on the hypermethylation of the AFP promoter and partially on the repressive transcription regulatory factor, ATBF1.
Finally, we examined the expression and localization of AFP and ATBF1 in resected clinical samples (AFP-GC cases). The gastric tumor, which showed deep in®ltration invading the subserosa, consisted of welldierentiated tubular adenocarcinoma admixed with foci of poorly dierentiated adenocarcinoma showing solid growth of tumor cells. The tumor cells of poorly dierentiated adenocarcinoma had immunoreactive AFP which was absent in the well-dierentiated tubular adenocarcinoma. On the contrary, ATBF1 immunoreactivity was present in the tumor cells of the well-dierentiated tubular adenocarcinoma, but not in those of the poorly dierentiated adenocarcinoma (Figure 4) . The immunohistochemistry of clinical samples also revealed that AFP producing gastric cancer cells lack transcription factor ATBF1.
ATBF1 has many DNA binding domains consisting of four homeoboxes and 23 zinc ®ngers, so ATBF1 can bind many genes in addition to the AFP gene. It was reported that ATBF1 interacts with c-Myb oncoprotein via protein-protein interaction and represses its transcriptional activity (Kaspar et al., 1999) . C-Myb is associated with the growth and survival of cancer cells through induction of cyclooxygenase-2 (COX-2) and Bcl-2 (Ramsay et al., 2000; Salomoni et al., 1997) . The lack of ATBF1 in AFP-GC cells may promote the activities of several oncoproteins, including c-Myb, resulting in the high malignant nature.
We conclude that the absence of ATBF1, a characteristic of AFP-GC, induces AFP gene expression in gastric cancer and might be responsible for the extremely malignant phenotype of AFP-GC.
Abbreviations AFP, Alpha-Fetoprotein; AFP-GC, Alpha-Fetoprotein producing gastric cancer; ATBF1, AT motif binding factor 1; HNF1, hepatocyte nuclear factor 1; CAT, chloramphenicol acetyltransferase. Immunohistochemistry was performed using the labeled streptavidin-biotin complex system (Histo®ne SAB-PO kit; Nichirei, Tokyo, Japan) to detect AFP and ATBF1-A. An anti-ATBF1 antisera was produced by immunizing a recombinant peptide composed of 41 amino acids corresponding to residues 2114 ± 2154 of mouse ATBF1 (Ido et al., 1996) fused to glutathione Stransferase. The sequence of this 41 amino-acid peptide is 100% identical with that of human ATBF1 (amino acids 2107 ± 2147). The antisera were fractionated through protein A column to obtain IgG. 
